Biopharma GettyImages-1134447601.jpg
Our Work

Latham Advises on Bormioli Pharma’s €350 Million Bond Offering

May 12, 2023
A cross-border team represented the initial purchasers on the €350 million notes issuance.

Latham & Watkins has advised BNP Paribas, Goldman Sachs, Credit Agricole and Intesa Sanpaolo on the issuance of €350 million aggregate principal amount of senior secured floating rate notes due May 2028, by Bormioli Pharma S.p.A., a Triton portfolio company and leader in the production of pharmaceutical packaging. 

The proceeds of the notes were used to, among other things, redeem the company’s existing senior secured notes due 2024. Bormioli Pharma’s existing noteholders were offered the option to participate in the new issuance through the cashless rollover of the existing notes held by them. The notes were listed as of the issue date on the Luxembourg Stock Exchange and admitted to trading on the Euro MTF market thereof. 

The Latham & Watkins team was led by Milan corporate partners Jeff Lawlis and Paolo Bernasconi, together with associates Jackie Yonover and Riccardo Perris, with respect to US corporate law matters. Advice on Italian finance matters was provided by Milan partners Marcello Bragliani and Alessia De Coppi, with associates Erika Brini Raimondi and Pasquale Spiezio; on English law finance matters by London partner Hendrik Smit, with associates Philipp Hagenbuch, Mark Walker, Cedric Oulai and Christina Nasioutzik; on US tax matters by New York partner Jocelyn Noll, with associate Farrah Yan; on regulatory matters by Milan partner Cesare Milani, with associates Edoardo Cassinelli, Irene Terenghi and Giulio Catalani; and on Italian capital markets matters by Milan corporate partner Antonio Coletti and associate Marco Bonasso.